Cryoport Q3 2026 Earnings: Revenue Rises 14% as Adjusted EBITDA Turns Positive

Cryoport (NASDAQ: CYRX) reported Q3 2026 revenue of $50.2 million, up 14% from $44.2 million, while basic and diluted net loss attributable to common stockholders widened to $0.25 per share from $0.18. Life Sciences Services led the revenue increase, and adjusted EBITDA from continuing operations turned positive, but a negative swing in other income and expense contributed to a wider GAAP net loss. The company also raised its full-year revenue guidance.

Core Financial Results

For the quarter ended September 30, 2026, Cryoport added approximately $6.0 million of revenue year over year. Gross profit increased, although total gross margin declined by 70 basis points as weaker product margins outweighed an improvement in service margins.

The company completed the divestiture of CRYOPDP in June 2025. CRYOPDP is classified as a discontinued operation for all periods, while adjusted EBITDA is presented from continuing operations.

Business and Segment Performance

Life Sciences Services generated 57% of quarterly revenue and grew faster than Life Sciences Products. BioStorage/BioServices was the fastest-growing disclosed business, while BioLogistics benefited from commercial therapy development and continued clinical-trial progress in cell and gene therapy.

Revenue from commercial cell and gene therapy clients increased 20%. At quarter-end, Cryoport supported 23 commercial therapies and 788 clinical trials, up by 43 trials from 745 a year earlier. The total included 99 Phase 3 trials, compared with 83 in Q3 2025.

During the quarter, customer Replimune received accelerated FDA approval for TUDRIQEV, while CRISPR Therapeutics and Vertex received supplemental approval expanding the CASGEVY label. Two customers also submitted Biologics License Applications. Cryoport said it anticipated five additional possible BLA or Marketing Authorization Application filings during 2026, alongside two possible approvals in Q4 and one possible supplemental geographic approval.

Profitability, Liquidity, and the Balance Sheet

Life Sciences Services gross margin improved to 50.4% from 49.7%, an increase of 70 basis points. Life Sciences Products gross margin fell to 43.6% from 46.4%, a 280-basis-point decline that more than offset the service-margin improvement and pulled consolidated gross margin lower.

Cryoport ended the quarter with $279.2 million of cash and cash equivalents and $113.9 million of short-term investments, for total reported liquidity of $393.1 million. That was down approximately $18.1 million from the combined $411.2 million held at December 31, 2025. The balance sheet also included $186.0 million of convertible senior notes classified as a current liability.

Operating Progress Did Not Translate into a Narrower GAAP Loss

The underlying operating figures improved despite the wider bottom-line loss. Gross profit increased by approximately $2.5 million while operating expenses rose by about $1.4 million, allowing the operating loss to narrow from $9.9 million to $8.8 million. Adjusted EBITDA from continuing operations also moved above zero.

The deterioration occurred below the operating line. Other income and expense, net, swung from income of $0.5 million to an expense of $4.4 million. Cryoport’s non-GAAP reconciliation included a $4.2 million unrealized investment loss in Q3 2026, compared with a $0.7 million unrealized gain a year earlier. This helps explain why GAAP loss from continuing operations widened even as operating loss and adjusted EBITDA improved.

Full-Year 2026 Guidance

Cryoport raised its full-year revenue outlook, citing year-to-date performance, expanding commercial therapy support, customer relationships, the clinical-trial pipeline, and demand for MVE products.

Based on nine-month revenue of $147.0 million, the guidance range implies approximately $50.0 million to $52.0 million of fourth-quarter revenue, with a midpoint of about $51.0 million.

Recent Insider Transactions

The supplied six-month insider summary showed 76,400 shares purchased across five transactions and 256,441 shares sold across four transactions. That produced net selling of 180,041 shares, equivalent to 8.40% of reported insider holdings of approximately 1.95 million shares.

The latest 10 reported transactions comprised four sales, four stock awards, and two derivative-security conversions. These transactions are presented as reported and do not, by themselves, establish insiders’ views about the company’s valuation or outlook.

Risks Investors Should Monitor

• Product-margin pressure: Life Sciences Products gross margin declined by 280 basis points and caused consolidated gross margin to fall despite better service margins.
• Continued GAAP losses: Adjusted EBITDA turned positive, but Cryoport remained unprofitable under GAAP. Investment-value fluctuations also created material volatility below the operating line.
• Clinical and regulatory timing: Growth in the cell and gene therapy business depends partly on customers advancing trials, obtaining approvals, and commercializing therapies. The possible filings and approvals identified by management remain uncertain.
• Guidance sensitivity: Cryoport said its outlook could be affected by macroeconomic and geopolitical conditions, supply-chain constraints, inflation, tariffs, trade restrictions, and foreign-exchange movements.
• Near-term balance-sheet obligation: The $186.0 million current portion of convertible senior notes is significant, even with $393.1 million of cash, equivalents, and short-term investments.

Summary

Cryoport’s Q3 2026 results showed improving operating momentum: services led double-digit revenue growth, the supported clinical-trial portfolio expanded, and adjusted EBITDA became positive. The main offsets were lower product margins and non-operating investment losses that widened the GAAP deficit. Execution against the raised revenue guidance, product-margin trends, regulatory progress among cell and gene therapy customers, and conversion of operating improvements into sustained GAAP profitability are the central items to monitor.